Ax–101 is a small molecule immuno-oncology drug with potent anti-tumor activity when used as a single agent, dramatically reducing the size of lymphoma in some patients and stabilizing growth in others with intact immune systems while causing no significant drug related adverse effects. In animals, Ax-101 has been shown to act synergistically with anti-PD-1 drugs. Co-therapy of Ax-101 and an anti-PD-1 drug resulted in improved outcomes for multiple cancers, including increase cure, greater tumor growth inhibition and, with respect to melanoma, immunity to re-challenge with the same cancer.
AxImmune anticipates completion of preclinical testing in Q2 2019.
Following completion of preclinical testing, AxImmune intends to file an IND with the FDA. AxImmune anticipates commencing clinical trials in Q4 2019. Plans are underway to conduct clinical trials at multiple sites.
The strong immuno-modulary action and synergistic effects of Ax-101 with ICI drugs has attracted an impressive group of key opinion leaders to join AxImmune’s Medical and Scientific Advisory Board.